Abstract: Objective To observe the effects of Sacubitril Valsartan Sodium Tablets on ventricular remodeling, plasma micrornA-423-5p (miR-423-5p) and soluble stroma-lysin 2 (sST2) in patients with chronic heart failure (CHF). 
 Methods A total of 112 patients with CHF who were treated in hospital from May 2021 to May 2022 were grouped according to the random number table method. Fifty-six patients in the single treatment group received basic treatment, and 56 patients in the combination treatment group received Sacubitril Valsartan Sodium Tablets on the basis of single treatment group. Galactolectin 3 (Gal-3), angiotensin Ⅱ (AngⅡ), soluble stroma-lysin 2 (sST2), matrix metalloproteinase-9 (MMP-9), pentameter protein-3 (PTX-3), glutathione peroxidase 3 (GPX-3), chromogranin A (CgA), total antioxidant capacity (T-AOC), miR-423-5p, malonaldehyde (MDA), left ventricular ejection fraction (LVEF), left ventricle average energy loss (EL-ave), left ventricular myocardial mass index (LVMI) level, 6 min walking test (6MWT) and Minnesota Living with Heart Failure Questionnaire score (MLHFQ) were detected before and after treatment. Clinical efficacy of the single treatment group and the combination treatment group were compared. 
 Results MDA level in combination treatment group was significantly lower than that in single treatment group (P＜0.05), while GPX-3 and T-AOC levels in combination treatment group were significantly higher than that in single treatment group (P＜0.05). The levels of Gal-3, miR-423-5p, sST2 and CgA in combination treatment group were significantly lower than those in single treatment group (P＜0.05), and the levels of MMP-9, AngⅡ and PTX-3 in combination treatment group were lower than those in single treatment group (P＜0.05). The LVEF and EL-ave of the combination treatment group were higher than those of the single treatment group (P＜0.05), while the LVMI of the combination treatment group was lower than that of the single treatment group (P＜0.05). The MLHFQ score of the combination treatment group was lower than that of the single treatment group (P＜0.05), while the 6MWT of the combination treatment group was higher than that of the single treatment group (P＜0.05). The total effective rate of the combination treatment group (98.21%) was significantly higher than that of the single treatment group (89.29%) (P＜0.05). 
 Conclusion In the treatment of CHF patients, Sacubitril Valsartan Sodium Tablets can reduce oxidative stress and myocardial fibrosis damage, improve ventricular remodeling and cardiac function, and enhance patients′ quality of life, activity endurance and clinical efficacy. 

Key words: heart failure, Sacubitril Valsartan Sodium Tablets, ventricular remodeling